Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Triple Negative Breast Neoplasms × parsaclisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 8 Lymphoma, Follicular 8 Lymphoma 7 Lymphoma, Large B-Cell, Diffuse 6 Lymphoma, B-Cell, Marginal Zone 5 Recurrence 4 Lymphoma, Mantle-Cell 4 Myeloproliferative Disorders 3 Primary Myelofibrosis 2 Hereditary Sensory and Autonomic Neuropathies 2 Breast Neoplasms 2 Advanced Malignancies 2 Unresectable or Metastatic Solid Tumors 1 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, T-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Head and Neck Neoplasms 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 B-Cell Malignancies 1

Interventions

pembrolizumab 139 Carboplatin 124 Paclitaxel 108 Cyclophosphamide 77 130-nm albumin-bound paclitaxel 58 Capecitabine 55 Doxorubicin 44 Gemcitabine 42 Albumin-Bound Paclitaxel 37 atezolizumab 35 Taxes 34 Cisplatin 32 Nivolumab 30 sacituzumab govitecan 28 Docetaxel 28 Epirubicin 27 Specimen Handling 25 olaparib 24 Bevacizumab 24 eribulin 23 durvalumab 23 Biopsy 22 Magnetic Resonance Spectroscopy 21 Drug Therapy 21 camrelizumab 20 toripalimab 17 Radiotherapy 14 liposomal doxorubicin 13 Everolimus 13 veliparib 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04142554 2020-11-03

LCCC1820

UNC Lineberger Comprehensive Cancer Center

Phase 1 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡